Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
MTS-105 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
MTS-105: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
68Ga-BBN-IRDye800CW Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
68Ga-BBN-IRDye800CW: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
FT751 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
FT751: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
JJH-201601 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
JJH-201601: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
TP53-EphA-2-CAR-DC vaccine(Chinese PLA General Hospital): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals
9 min read
Osteoarthritis (Yooyoung) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Osteoarthritis (Yooyoung): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key ri
9 min read
dualCAR-NK19/70 cell(Shanghai Tongji Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
dualCAR-NK19/70 cell(Shanghai Tongji Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market
9 min read
HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing
9 min read
LTP-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
LTP-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
BK Specific Cytotoxic T-cells(New York Medical College) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BK Specific Cytotoxic T-cells(New York Medical College): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deal
9 min read
Induced pluripotent stem cell-derived extracellular vesicles(Shanghai Sixth People's Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Induced pluripotent stem cell-derived extracellular vesicles(Shanghai Sixth People's Hospital): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers c
9 min read
Mesenchymal Stem Cells from Wharton´s jelly(Fundación Neumologica Colombiana) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Mesenchymal Stem Cells from Wharton´s jelly(Fundación Neumologica Colombiana): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical developme